# US 2019/0054148 A1 · Novel cell membrane-permeating peptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0054148 A1
- Document ID: US20190054148A1
- Status: Published application
- Kind: A1
- Application number: 15/575,331
- Filed: 2016-05-18
- Published: 2019-02-21
- Earliest claimed: 2015-05-19
- Assignees: National University Corporation Kumamoto University
- Applicants: National University Corporation Kumamoto University
- Inventors: Shingo ITO; Sumio OHTSUKI
- Web page: https://patentgrep.com/patent/US20190054148A1

## CPC

- A61K 38/28: Insulins
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/64: Cyclic peptides containing only normal peptide links
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2795/14121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/14131: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention addresses to provide a novel membrane permeability-improving agent which can be applied to high molecular drugs. More specifically, the present invention addresses to provide: a drug carrier which can improve the absorption efficiency of a high molecular drug in the small intestine; and a membrane permeation-improving agent containing the carrier. According to the present invention, a cell membrane-permeating peptide can be provided, which comprises an amino acid sequence selected from the group consisting of the following amino acid sequences: DNPGN (SEQ ID NO: 1); SRPAF (SEQ ID NO: 2); NDPRN (SEQ ID NO: 3); and MSVAN (SEQ ID NO: 4). According to the present invention, a cell membrane-permeable composition can also be provided, which comprises the peptide and a biologically active substance.

## Claims

### Claim 1

A cell membrane-permeable peptide comprising an amino acid sequence selected from the group consisting of amino acid sequences: DNPGN (SEQ ID No: 1), SRPAF (SEQ ID No: 2), NDPRN (SEQ ID No: 3) and MSVAN (SEQ ID No: 4).

### Claim 2 (depends on 1)

The cell membrane-permeable peptide according to claim 1, wherein the peptide comprises at least one unnatural amino acid.

### Claim 3 (depends on 1)

The cell membrane-permeable peptide according to claim 1, wherein the peptide comprising an amino acid sequence is selected from the group consisting of amino acid sequences: DNPGNET (SEQ ID No: 5), TVSRPAF (SEQ ID No: 6), HSNDPRN (SEQ ID No: 7) and PFMSVAN (SEQ ID No: 8).

### Claim 4 (depends on 1)

The cell membrane-permeable peptide according to claim 1, wherein the amino acid sequence is DNPGN (SEQ ID No: 1) or DNPGNE (SEQ ID No: 9).

### Claim 5 (depends on 1)

The cell membrane-permeable peptide according to claim 1, wherein the peptide is a cyclic peptide.

### Claim 6 (depends on 5)

The cell membrane-permeable peptide according to claim 5, wherein the cyclic peptide contains a Cys-Cys disulfide bond.

### Claim 7 (depends on 1)

The cell membrane-permeable peptide according to claim 1, wherein the peptide permeates small intestine epithelial cells of mammals.

### Claim 8

A cell membrane-permeable composition comprising:
a peptide comprising an amino acid sequence selected from the group consisting of amino acid sequences: DNPGN (SEQ ID No: 1), SRPAF (SEQ ID No: 2), NDPRN (SEQ ID No: 3) and MSVAN (SEQ ID No: 4), and
a biologically active substance,
wherein the peptide binds to or forms a complex with the biologically active substance or an active substance carrier containing the biologically active substance.

### Claim 9 (depends on 8)

The composition according to claim 8, wherein the peptide comprises at least one unnatural amino acid.

### Claim 10 (depends on 8)

The composition according to claim 8, wherein the peptide comprises an amino acid sequence selected from the group consisting of amino acid sequences: DNPGNET (SEQ ID No: 5), TVSRPAF (SEQ ID No: 6), HSNDPRN (SEQ ID No: 7) and PFMSVAN (SEQ ID No: 8).

### Claim 11 (depends on 8)

The composition according to claim 8, wherein the amino acid sequences is DNPGN (SEQ ID No: 1) or DNPGNE (SEQ ID No: 9).

### Claim 12 (depends on 8)

The composition according to claim 8, wherein the peptide is a cyclic peptide.

### Claim 13 (depends on 12)

The composition according to claim 12, wherein the cyclic peptide contains a Cys-Cys disulfide bond.

### Claim 14 (depends on 8)

The composition according to claim 8, wherein the biologically active substance is a protein.

### Claim 15 (depends on 8)

The composition according to claim 8, wherein the biologically active substance is a biologically active peptide.

### Claim 16 (depends on 15)

The composition according to claim 15, wherein the biologically active peptide is insulin.

### Claim 17 (depends on 8)

The composition according to claim 8, wherein the biologically active substance is a nucleic acids.

### Claim 18 (depends on 17)

The composition according to claim 17, wherein the nucleic acids is antisense DNA, siRNA or shRNA.

### Claim 19 (depends on 8)

The composition according to claim 8, wherein the active substance carrier containing the biologically active substance is a liposome.

### Claim 20 (depends on 8)

The composition according to claim 8, wherein the active substance carrier containing the biologically active substance is a cyclodextrin.
